Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis by Raffone, Antonio et al.
Vol.:(0123456789) 
Archives of Gynecology and Obstetrics (2019) 299:1233–1242 
https://doi.org/10.1007/s00404-019-05103-1
REVIEW
Endometrial hyperplasia and progression to cancer: which 
classification system stratifies the risk better? A systematic review 
and meta‑analysis
Antonio Raffone1 · Antonio Travaglino2 · Gabriele Saccone1 · Luigi Insabato2 · Antonio Mollo1 · 
Giuseppe De Placido1 · Fulvio Zullo1
Received: 10 September 2018 / Accepted: 22 February 2019 / Published online: 27 February 2019 
© Springer-Verlag GmbH Germany, part of Springer Nature 2019
Abstract
Purpose Benign and precancerous endometrial hyperplasias (EH) are differentiated thorough two possible histomorphologic 
classifications: WHO (adopting the subjective evaluation of cytologic atypia) and EIN (adopting several histomorphologic 
parameters, evaluable subjectively, or objectively with a computerized analysis calculating a prognostic score, the D score). 
ACOG recommends the use of EIN system although no distinction was made between objective assessment (not widely 
available), and subjective assessment (more applicable in the common practice). Moreover, it is still unclear if subjective 
EIN system is actually preferable to WHO classification. We aimed to assess the reliability of WHO system, D score and 
subjective EIN system in stratifying the risk of progression to cancer in EH.
Methods MEDLINE, EMBASE, Web of Sciences, Scopus, ClinicalTrial.gov, OVID, Cochrane Library and Google Scholar 
were searched for relevant articles from the inception to August 2018. All studies assessing the rates of progression of EH 
to cancer were included.
Results Twelve cohort studies and one case–control study, assessing 3629 EH, were included. Relative risk (RR) for cancer 
progression was calculated with 95% confidence interval (CI), and results were compared using Chi-square test (significant 
p value < 0.05). WHO system showed a RR of 8.74 (95% CI 6.66–11.47). Objective D score showed a RR of 29.22 (95% CI 
13.24–64.51), significantly higher than WHO (p = 0.005). Subjective EIN system showed a RR of 19.37 (95% CI 5.86–64.01), 
intermediate between WHO and D score, without significant differences (p = 0.20 and p = 0.57, respectively).
Conclusion Objective EIN criteria with D score are significantly more reliable than WHO criteria in stratifying the risk of 
progression of EH to cancer. Subjective EIN criteria did not show significant superiority over WHO instead. Further studies 
are necessary to determine if subjective EIN system should replace WHO system in the routine diagnosis of EH.
Keywords World Health Organization · Endometrial intraepithelial neoplasia · Endometroid adenocarcinoma · Endometrial 
precancer · Prognosis · Concurrent cancer
Introduction
Endometrial hyperplasia (EH) is an irregular proliferation of 
endometrial glands, which can progress to endometrial cancer 
(EC) [1, 2]. The risk of progression of EH to EC depends on 
the nature of the lesion, which can be a benign reaction to an 
unopposed action of estrogens, or a neoplastic premalignant 
process [2, 3]. These two conditions require two different ther-
apeutic approaches: benign EH may be managed with obser-
vation alone, with progestin reserved to symptomatic cases 
[4]. On the other hand, premalignant EH should be treated 
with hysterectomy, although a conservative treatment can be 
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chosen in selected cases (strong wish to preserve fertility or 
contraindication for surgery) [3, 4].
The diagnosis of benignity or premalignancy of EH is usu-
ally made at histologic examination [2]. The most used clas-
sification system for differentiating premalignant EH is the 
one proposed by the World Health Organization (WHO) and 
repeatedly revised [2, 5, 6]. WHO system identifies cytologic 
atypia as the crucial criterion of premalignancy, indicating 
atypical EH as premalignant and non-atypical EH as benign 
[1, 2].
“Endometrial intraepithelial neoplasia” (EIN) is an alterna-
tive system which was proposed to overcome several problems 
risen for WHO criteria, such as low reproducibility and lack 
of a pathogenetic and molecular basis [2, 3, 6]. EIN system is 
based on nuclear and architectural features of EH, which can 
be objectively assessed through a computerized morphometric 
analysis calculating a prognostic score, the D score [3, 6]. D 
score takes into account volume percentage stroma, variability 
of nuclear axis and outer glandular perimeter, and classifies 
EH as “benign” if D score ≥ 1, and “EIN” if D score < 1 [2, 6]. 
Nonetheless, D score is not widespread, because of the costs 
of a morphometry workstation [6]. A subjectively assessable 
surrogate of EIN system was developed to allow a simpler and 
wider applicability of such system [3]. Subjective EIN crite-
ria of precancer include increased gland to stroma ratio, dis-
tinct cytology compared to the adjacent endometrium, lesion 
size > 1 mm, exclusion of benign mimics and cancer [3].
The Royal College of Obstetricians and Gynaecologists 
(RCOG) recommends the use of WHO system to diagnose 
premalignant EH [4].
In contrast, the American College of Obstetricians and 
Gynecologists (ACOG) recommends the use of EIN system 
[7] since several studies support its better reproducibility 
and accuracy compared to WHO system [8–11]. However, 
ACOG makes no differentiations between objective D score 
and subjective EIN criteria [7]. Most of these studies referred 
to objective D score, while other studies showed for WHO and 
subjective EIN system similar accuracy [12, 13] and reproduc-
ibility [14].
It is still unclear which classification system of EH should 
be globally used to direct the management of the patients. In 
this respect, it should be determined which system better pre-
dicts the risk of progression to cancer, to identify patients who 
actually need treatment.
The aim of our study was to assess the reliability of WHO 
system, D score and subjective EIN system in stratifying the 
risk of progression to cancer in EH.
Materials and methods
Study protocol
This study was designed according to a protocol for sys-
tematic review and meta-analysis. Methods for collection, 
extraction and analysis of data were designed a priori. All 
review stages were conducted independently by two review-
ers (AT, AR). Disagreements were resolved by discussion 
with a third reviewer (GS).
The study was reported following the Preferred Reporting 
Item for Systematic Reviews and Meta-analyses (PRISMA) 
statement [15].
Search strategy
MEDLINE, EMBASE, Web of Sciences, Scopus, Clini-
calTrial.gov, OVID, Cochrane Library and Google Scholar 
were searched for relevant articles from the inception of 
each database to August 2018. Several researches were made 
using a combination of the following text words found on 
Medical SubHeading (MeSH) vocabulary: “endometr*”; 
“hyperplasia”; “intraepithelial neoplasia”; “EIN”; “WHO”; 
“cancer”; “adenocarcinoma”; “precancer”; “premalignant”; 
“precursor”; “predict*”; “prognos*”; “progression”; “devel-
opment”; “risk”; “hysterectomy”. References from relevant 
articles were also reviewed.
Study selection
We included all peer-reviewed, retrospective or prospective 
studies assessing the rates of progression of EH to cancer.
Exclusion criteria were
1. Assessment of only those EH undergone hysterectomy 
as primary treatment.
2. Inclusion of only benign or only premalignant EH.
3. EH not classified.
4. Classification system other than WHO or EIN.
5. Reviews.
6. Same cohort of patients as a study already included.
Risk of bias assessment
The risk of bias was assessed following the revised Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS-2) 
[16]. Four domains related to risk of bias were assessed in 
each study: (1) patient selection (if consecutive patients were 
included); (2) index diagnosis (if endometrial sampling was 
performed with the same method for all patients), (3) refer-
ence diagnosis (if the progression to cancer was confirmed 
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on a subsequent hysterectomy), (4) flow and timing (if all 
patients were followed for at least 1 year since earlier can-
cers should be considered as already present at the time of 
first biopsy [9, 12]). Authors’ judgment was “low risk”, 
“high risk” or “unclear risk of bias” for each domain.
Data extraction
Data were extracted without modifications and reported in 
2 × 2 contingency tables for each study. Within tables, two 
dichotomous qualitative variables were reported:
• EH category (“benign” or “premalignant”);
• Progression to cancer (“no cancer” or “cancer”).
For the studies adopting WHO criteria, EH without atypia 
(simple or complex) was considered as “benign”, while atyp-
ical EH (simple or complex) as “premalignant”.
For the studies adopting objective EIN criteria based on 
D score, D ≥ 1 was considered as “benign”, and D < 1 as 
“premalignant”.
For the studies adopting subjective EIN criteria, benign 
EH was considered as “benign” and EIN as “premalignant”.
If discrepancies between values reported in the text and 
the tables were found, values from tables were used for the 
analysis.
Data analysis
The reliability of classification systems was assessed by cal-
culating relative risk (RR) for progression to cancer. Values 
were reported for each study and as pooled estimate on forest 
plots, with 95% confidence interval (CI). A p value < 0.05 
was considered significant.
Statistical heterogeneity among studies was assessed 
using the inconsistency index I2: heterogeneity was consid-
ered insignificant for I2 < 25%, low for I2 < 50%, moderate 
for I2 < 75% and high for I2 ≥ 75%. The random effect model 
of DerSimonian and Laird was used only if I2 > 50%; other-
wise, a fixed-effect model was adopted.
Review Manager 5.3 (Copenhagen: The Nordic Cochrane 
Centre, Cochrane Collaboration, 2014) was used for the 
analysis.
Results
Selection and characteristics of the studies
Thirteen retrospective studies with a total of 3629 EH were 
included [9–12, 17–25]. For classification of EH, WHO cri-
teria were used in 11 studies (reporting also complexity of 
glandular architecture in 8), D score in 8, and subjective 
EIN criteria in 3. The process of study selection is reported 
in Fig. 1.
One study adopted a case–control design [12]; the others 
followed a retrospective cohort design. Sample size ranged 
from 39 to 1443. Sampling methods for index test included 
curettage in 11 studies, Pipelle biopsy in 2, hysteroscopic 
biopsy in 2, vacuum aspiration in 1.
Characteristics of the included studies are detailed in 
Table 1.
Risk of bias assessment
Results of risk of bias assessment are shown in Fig. 2.
For the “patient selection” domain, the risk of bias was 
high for one study, because its design (case–control with 
oversampling of atypical AH [12]) makes it unsuitable for 
comparison with other studies. Three studied were consid-
ered at unclear risk since they selected only EH with com-
plex glandular architecture.
For the “index diagnosis” domain, five studies were con-
sidered at unclear risk since they did not report the index 
sampling methods, or because they used different ones.
For the “reference diagnosis” domain, nine studies 
were considered at unclear risk, because they did not 
Fig. 1  Flow diagram of studies identified in the systematic review 
[Prisma template (Preferred Reporting Item for Systematic Reviews 
and Meta-analyses)]
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specify if all cancer diagnoses were confirmed on hys-
terectomy specimens.
For the “flow and timing” domain, eight studies were 
considered at unclear risk since they also included some 
patients with a follow-up < 1 year.
All remaining judgments for each domain were “low 
risk of bias”.
Meta‑analysis
Twelve studies were included in the meta-analysis since the 
only study at high risk of bias was excluded.
The group of EH classified according to WHO system 
consisted of 3384 EH from ten studies; heterogeneity among 
studies was low (I2 = 45%). Pooled RR for progression to 
cancer was 8.74 (95% CI 6.66–11.47).
The group of EH classified according subjective EIN cri-
teria consisted of 236 EH from 2 studies, with no heteroge-
neity among studies (I2 = 0%). Pooled RR was 19.37 (95% 
CI 5.86–64.01), not significantly higher than WHO subgroup 
(χ2 = 1.62; p = 0.20).
The group of EH classified using D score consisted of 
1106 EH from 6 studies; heterogeneity was insignificant 
(I2 = 5%). Pooled RR was 29.22 (95% CI 13.24–64.51), sig-
nificantly higher than WHO subgroup (χ2 = 7.99; p = 0.005), 
but not than subjective EIN subgroup (χ2 = 0.32; p = 0.57).
Results are reported graphically in Fig. 3.
Discussion
Main findings and interpretations
Our study showed that objective EIN system based on D 
score better predicted the risk of cancer than WHO system. 
On the other hand, subjective EIN criteria showed interme-
diate reliability between WHO and objective EIN, without 
significant difference.
Classification of EH is a long-standing issue. Before 
1994, EH had been classified as “mild”, “moderate” and 
“severe”, or alternatively as “cystic glandular”, “adenoma-
tous” and “atypical adenomatous” [26]. The 1994 WHO 
classification system had categorized EH according to two 
parameters: glandular complexity and cytologic atypia. 
Therefore, four categories of EH were proposed: “simple 
non-atypical”, “complex non-atypical”, “simple atypical” 
and “complex atypical” [2, 5, 6]. Cytologic atypia was 
already considered as the main factor associated with risk 
of progression to cancer [17]. However, these categories did 
not reflect the dichotomous nature of EH, which can be a 
polyclonal proliferation caused by the action of estrogens 
or a neoplastic process [3]. EIN system was developed to 
resolve this issue, distinguishing “benign EH” and “EIN” 
based on the pathogenetic mechanism underlying EH [2, 3, 
6]. As already discussed, EIN system was first based on a 
computerized analysis calculating the prognostic “D score”, 
developed by Baak et al. [2, 18]. Subsequently, a subjec-
tive assessment of EIN criteria was proposed to ensure a 
wide applicability of such system in the routine histologic 
examination [6]. On the other hand, the WHO revised its 
classification in 2003, proposing three EH categories: 
Fig. 2  a Assessment of risk of bias. Summary of risk of bias for each 
study; plus sign: low risk of bias; minus sign: high risk of bias; ques-
tion mark: unclear risk of bias. b Risk of bias graph about each risk 
of bias item presented as percentages across all included studies
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“simple”, “complex” and “atypical” [5, 14]; such system 
was quite superimposable to those used before 1994 and 
mentioned above. Finally, in 2014, the WHO proposed a 
dichotomous classification of EH into “non-atypical” and 
“atypical”, reporting “EIN” as a synonym of the latter one 
[1, 2]. Therefore, WHO adopted the same conceptual basis 
as EIN system for EH categorization.
For WHO criteria, based on cytologic atypia, we found a 
RR for progression to cancer of 8.74. Objective EIN system 
based on D score showed a RR of 29.22, significantly higher 
than WHO (p = 0.005). Regarding subjective EIN system, 
we found a RR of 19.37, intermediate between WHO crite-
ria and D score. However, the difference was not significant 
compared to both WHO (p = 0.20) and D score (p = 0.57). 
In fact, results from the literature are conflicting in this field. 
In our previous studies, we found that loss of expression of 
Bcl-2 and PAX2 was more strongly associated with subjec-
tive EIN criteria of premalignancy than WHO ones [27, 28], 
while loss of PTEN was not [29]. In predicting progression 
to cancer, Hecht et al. [23] reported a clear superiority of 
subjective EIN system over WHO, while a large study by 
Lacey et al. [12] showed similar accuracy between the two 
systems. For stratifying the risk of coexistent cancer, Yang 
et al. [30] showed higher accuracy of subjective EIN system, 
while Salman et al. [13] reported no difference with WHO; 
in our previous meta-analysis, the accuracy was similar in 
Fig. 3  Forest plot of individual studies and pooled relative risk for progression to cancer for WHO system, subjective EIN system and objective 
EIN system (D score) for classification of endometrial hyperplasia
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the two systems, but they showed different values of sensi-
tivity and specificity [31]. Regarding the reproducibility of 
the two systems, a study by Ordi et al. [14] found no signifi-
cant differences between the two.
Based on these results, we support that a difference 
should always be made between the objective and subjec-
tive EIN systems. The first showed indeed clearly higher 
reliability than WHO system, but is not widely applicable 
in the routine practice. Regarding the second, the overall 
evidence of its superiority over WHO is not robust enough.
In this regard, it should be remarked that our previous 
meta-analysis showed that the subjective EIN system was 
more sensitive, but less specific than WHO system in strati-
fying the risk of coexistent cancer in EH. This finding may 
indicate that subjective EIN criteria identify precancerous 
lesions in an earlier phase compared to WHO criteria [31]. 
If this supposition is true, subjective EIN system might actu-
ally reveal higher accuracy than WHO for the risk of cancer 
on the long term. However, the currently available data are 
insufficient to draw such a conclusion, and further studies 
are needed before recommending a change in the diagnostic 
approach to EH.
Anyway, when a possible replacement of WHO system by 
EIN system is discussed, confusion between objective and 
subjective assessments should be avoided.
Strengths and limitations
To the best of our knowledge, this is the first meta-analysis 
evaluating the reliability of WHO system, D score and sub-
jective EIN system in stratifying the risk of progression to 
cancer in EH.
However, several factors may affect our results, especially 
regarding the poor uniformity of methods among studies.
The different duration of follow-up might be the main 
limitation for our study since the cumulative risk of pro-
gression might be increasing over time [32]. However, such 
limitation may be tempered with the fact that most progres-
sions occur early. In this regard, Horn et al. [21] pointed out 
that the rates of progression reported by the several studies 
in the literature tend to be constant, regardless of the follow-
up duration.
Some studies also included some patients with a follow-
up < 1 year. Such duration may be inadequate for assess-
ing progression since endometrial cancer has a low growth 
rhythm and the progression rates may be underestimated. 
Furthermore, cancers occurred within 1  year from EH 
biopsy are usually considered as “coexistent” rather than 
“subsequent” [9, 12].
Progression rates might also be influenced by differences 
in the patient management (e.g., type of progestin adminis-
tered or combination with hysteroscopic resection) [33–36]; 
unfortunately, patient management in the included studies 
was not detailed enough to allow a subgroup analysis.
In the large multicentre study by Baak et al. [9], a minor 
part of patient data overlapped with some previous studies; 
unfortunately, such data are not separable from the total. 
While in some studies the data overlap was clear, and con-
sequently they were excluded from the analysis [37–40], 
overlap risk was not assessable for other studies [10, 25].
Finally, the low number of studies that used subjective 
EIN criteria was a major limitation to our results.
Conclusion
Among the classification systems of EH, objective EIN cri-
teria with D score calculation are significantly more reliable 
than WHO criteria in stratifying the risk of progression of 
EH to cancer. Subjective EIN criteria, which are more appli-
cable in the common practice than D score, did not show 
significant superiority over WHO instead. Further studies 
are necessary to determine if subjective EIN system should 
replace WHO system in the routine diagnosis of EH.
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